CRISPR Therapeutics AG

CRISPR Therapeutics AG is a gene editing company that develops gene-based medicines using its proprietary CRISPR/Cas9 platform. The company's portfolio includes therapeutic programs for hemoglobinopathies, oncology, regenerative medicine, and rare diseases. Its lead product candidate, CTX001, is an ex vivo CRISPR gene-edited therapy for transfusion-dependent beta-thalassemia and severe sickle cell disease. Additionally, the company develops gene-edited allogeneic CAR-T investigational therapies for various malignancies and solid tumors, as well as immune-evasive stem cell-derived product candidates for type 1 diabetes. CRISPR Therapeutics AG generates revenue through strategic partnerships with companies like Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and others.

Products

• CTX001 - ex vivo CRISPR gene-edited therapy

• CTX110, CTX120, CTX130 - gene-edited allogeneic CAR-T investigational therapies

• VCTX210 - gene-edited immune-evasive stem cell-derived product candidate